News Recap: Agile Therapeutics, Inc. (NASDAQ:AGRX); Daseke, Inc. (NASDAQ:DSKE)
By
James -
December 18, 2018
25
Agile Therapeutics, Inc. (NASDAQ:AGRX)
Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company’s lead product candidate is Twirla (TM); also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Agile Therapeutics, Inc. is headquartered in Princeton, New Jersey.
Agile Therapeutics, Inc. (NASDAQ:AGRX)’s Financial Overview
Agile Therapeutics, Inc. (NASDAQ) declined -12.16% yesterday to close its trading session at $0.65. The company has 1 year Price Target of $3. Agile Therapeutics, Inc. has 52-Week high of $5.18 and 52-Week Low of $0.23. The stock touched its 52-Week High on 5.18 and 52-Week Low on 0.23. The stock traded with the volume of 727441 shares yesterday. The firm shows the market capitalization of $24.86 Million.
Agile Therapeutics, Inc. (NASDAQ) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $-0.11/share against the analyst consensus estimate of $-0.15/share. The difference between the actual and expected EPS is $0.04 a share with a surprise factor of 26.7%.
The firm is trading with SMA20 of -21.66 Percent, SMA50 of -20.75 Percent and SMA200 of -46.18 percent. Agile Therapeutics, Inc. has P/S value of 0 while its P/B value stands at 0.97. Similarly, the company has Return on Assets of -54.9 percent, Return on Equity of -76.3 percent and Return on Investment of 0 Percent. The company shows Gross Margin and Operating Margin of 0 percent and 0 percent respectively.
The Stock currently has Analyst’ mean Recommendation of 2.4 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 3 analysts offering 12-month price forecasts for Agile Therapeutics Inc have a median target of 3.00, with a high estimate of 4.00 and a low estimate of 3.00. The median estimate represents a +361.54% increase from the last price of 0.65.
Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.
AI
